Observational studyCancer medicine2024

Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis.

Yasuyuki Ikezawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.